A new light on antibiotic resistance
Using the power of genomics and informatics to fight antibiotic-resistant microbes
Optimizing Genomic Testing for Antibiotic Resistance
Existing tests can take days to identify the correct treatment for a patient’s infection. That’s why caregivers often use broad-spectrum antibiotics as a first defense—but when those drugs are overused, antibiotic-resistant microbes can emerge. OpGen is developing a better way to treat infection while preventing antibiotic resistance. We harness the power of informatics and genomics to identify antimicrobial resistant (AMR) organisms quickly and accurately, with an aim to improve treatment at the patient, hospital, and network level.
Deaths each year from bacterial infections (WHO)
Deaths annually in the us & europe from drug-resistant infections
Excess direct healthcare costs in the us from drug-resistant infections
OpGen Provides Update on Curetis Group Business Receiving U.S. FDA 510(k) Clearance of its Unyvero LRT for BAL Specimens MORE
OpGen Provides Curetis Group Business Update and Announces Completion of Key Milestones in Planned Business Combination MORE
OpGen Products in Development to Address “Urgent Threat” Pathogens Highlighted in New CDC Report on Antibiotic Resistance Threats MORE
There are currently no upcoming events.